NCT06233110 - Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 1, 2029

Study Completion Date

July 1, 2029

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG

Fostamatinib

Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

DRUG

Ruxolitinib

Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Trial Locations (1)

27710

RECRUITING

Duke, Durham